Over the past decade, lung cancer treatment has undergone a major paradigm shift. A
greater understanding of lung cancer biology has led to the development of many effective …

Molecular testing has become a mandatory component of the non-small cell lung cancer
(NSCLC) management. The detection of EGFR, BRAF and MET mutations as well as the …

Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat
non-small cell lung cancer (NSCLC) patients, based on their significant overall survival (OS) …

In the past decade, the introduction of molecularly targeted agents and immune-checkpoint
inhibitors has led to improved survival outcomes for patients with advanced-stage lung …

Profiling of circulating tumor DNA (ctDNA) in the bloodstream shows promise for
noninvasive cancer detection. Chromatin fragmentation features have previously been …

Although treatment of non-small cell lung cancer (NSCLC) with immune checkpoint
inhibitors (ICIs) can produce remarkably durable responses, most patients develop early …

Tumor microenvironment (TME) has been reported to exhibit a crucial effect in lung cancer.
Therefore, this study was aimed to investigate the genes associated with TME and develop a …

Simple Summary The abundance and the dynamic of the studies on NSCLC require
frequent summaries of the current achievements in the field. In our review, we aimed to …

Immune checkpoint inhibitor (ICI) therapies have revolutionized the management of patients
with NSCLC and have led to unprecedented improvements in response rates and survival in …

Non-small cell lung cancer is one of the most common types of malignances worldwide and
the main cause of cancer-related deaths. Current treatment for NSCLC is based on surgical …